

Global Cell Therapy for Solid Tumor Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/GBD7CCAE4C79EN.html>

Date: July 2026

Pages: 91

Price: US\$ 3,660.00 (Single User License)

ID: GBD7CCAE4C79EN

Abstracts

The global Cell Therapy for Solid Tumor market size is predicted to grow from US\$ 1971 million in 2025 to US\$ 7851 million in 2032; it is expected to grow at a CAGR of 20.9% from 2026 to 2032.

Cell Therapy for Solid Tumors refers to innovative biological therapies that use autologous or donor-derived immune cells, which are isolated, selected, expanded, genetically engineered, or functionally enhanced ex vivo and then reinfused into the patient to recognize, infiltrate, and kill solid tumor cells. This field includes tumor-infiltrating lymphocyte therapy, TCR-T cell therapy, CAR-T cell therapy, CAR-NK/NK cell therapy, and other engineered immune cell approaches, targeting solid tumors such as melanoma, lung cancer, liver cancer, gastrointestinal cancers, gynecologic tumors, sarcomas, and other refractory or relapsed malignancies. Compared with cell therapies for hematologic cancers, solid tumor cell therapy must overcome major barriers including tumor heterogeneity, antigen selection, immunosuppressive microenvironments, cell infiltration, and in vivo persistence. It represents a frontier direction in expanding cancer immunotherapy from blood cancers to the broader solid tumor market. The average gross profit margin of this product is 90%.

Cell therapy for solid tumors is at a critical inflection point, moving from clinical exploration toward commercial validation. With TIL therapy and engineered T cell therapies achieving regulatory breakthroughs in solid tumor indications, industry confidence is shifting from ?conceptually feasible? to ?clinically translatable and commercially actionable.? Solid tumors represent a broad patient population with high relapse and refractory rates, and substantial unmet needs remain after surgery, radiotherapy, chemotherapy, targeted therapy, and immune checkpoint inhibitors, creating an attractive market entry point for cell therapy. At the same time, advances in

single-cell sequencing, tumor antigen discovery, TCR screening, gene editing, cell expansion, and cold-chain logistics are pushing companies from single-product development toward platform-based strategies. For CEOs, marketing leaders, and investors, cell therapy for solid tumors is not only a next-generation oncology innovation field, but also a strategic industrial opportunity connecting precision diagnostics, cell manufacturing, hospital treatment centers, and long-term patient management.

The challenges of cell therapy for solid tumors are concentrated in scientific, manufacturing, and clinical complexity. Solid tumors are highly heterogeneous, tumor antigen expression can be unstable, and low-level antigen expression in normal tissues may create off-target risks. The tumor microenvironment, including immunosuppressive cells, hypoxia, fibrotic barriers, and metabolic stress, can limit therapeutic cell infiltration and sustained killing activity. On the manufacturing side, autologous cell products involve significant batch-to-batch variability, long production cycles, and strict release testing, placing high demands on process robustness, quality systems, and supply chain coordination. Commercially, companies must also address treatment-center development, physician training, adverse event management, patient screening, reimbursement systems, and treatment accessibility. Future competition will not be determined only by individual clinical results, but by whether companies can systematically solve challenges across target selection, cell engineering, scalable manufacturing, and clinical delivery.

Downstream demand for cell therapy in solid tumors will gradually expand from late-line, relapsed, and refractory patients toward more precise stratification and earlier-line treatment strategies. Oncology hospitals, comprehensive cancer centers, cell therapy centers, clinical research institutions, and regional medical centers are the most important application settings at the current stage. As companion diagnostics, HLA typing, tumor antigen testing, and cell therapy center capabilities mature, downstream customers will shift their focus from 'whether it works?' to 'which patients are suitable, whether the treatment workflow is controllable, whether responses are durable, whether safety is manageable, and whether it can be combined with immunotherapy or targeted therapy.' Cell therapy for solid tumors will no longer be viewed only as a last-line option, but may become a high-value module in multidisciplinary oncology treatment. Companies with clear indication positioning, strong clinical evidence, and treatment-center collaboration capabilities will be better positioned to build brand trust and market access advantages.

LPI (LP Information)' newest research report, the 'Cell Therapy for Solid Tumor Industry Forecast' looks at past sales and reviews total world Cell Therapy for Solid

Tumor sales in 2025, providing a comprehensive analysis by region and market sector of projected Cell Therapy for Solid Tumor sales for 2026 through 2032. With Cell Therapy for Solid Tumor sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Cell Therapy for Solid Tumor industry.

This Insight Report provides a comprehensive analysis of the global Cell Therapy for Solid Tumor landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Cell Therapy for Solid Tumor portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cell Therapy for Solid Tumor market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy for Solid Tumor and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy for Solid Tumor.

This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy for Solid Tumor market by product type, application, key players and key regions and countries.

Segmentation by Type:

CAR-T Therapy

TCR-T Therapy

TIL Therapy

CAR-NK Therapy

Tumor-Infiltrating NK Or T Cells

Other

Segmentation by Cell Source:

- Autologous Therapy
- Allogeneic Therapy
- Gene-Edited Therapy
- Armored Cell Therapy
- Combination Therapy
- Other

Segmentation by Indication:

- Melanoma Products
- Gastrointestinal Tumor Products
- Liver Cancer Products
- Lung Cancer Products
- Gynecologic Tumor Products
- Other

Segmentation by Application:

- Melanoma
- Lung Cancer
- Liver Cancer
- Gastric And Colorectal Cancer

Ovarian Cancer

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Iovance Biotherapeutics

Adaptimmune

Immatics

CARSgen Therapeutics

JW Therapeutics

Legend Biotech

Gracell Biotechnologies

Fosun Kite

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Cell Therapy for Solid Tumor Market Size (2021-2032)
- 2.1.2 Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032)
- 2.1.3 World Current & Future Analysis for Cell Therapy for Solid Tumor by Country/Region (2021, 2025 & 2032)

2.2 Cell Therapy for Solid Tumor Segment by Type

- 2.2.1 CAR-T Therapy
- 2.2.2 TCR-T Therapy
- 2.2.3 TIL Therapy
- 2.2.4 CAR-NK Therapy
- 2.2.5 Tumor-Infiltrating NK Or T Cells
- 2.2.6 Other
- 2.2.7 Cell Therapy for Solid Tumor Market Size by Type
 - 2.2.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

2.3 Cell Therapy for Solid Tumor Segment by Cell Source

- 2.3.1 Autologous Therapy
- 2.3.2 Allogeneic Therapy
- 2.3.3 Gene-Edited Therapy
- 2.3.4 Armored Cell Therapy
- 2.3.5 Combination Therapy

2.3.6 Other

2.3.7 Cell Therapy for Solid Tumor Market Size by Cell Source

2.3.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032)

2.3.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)

2.4 Cell Therapy for Solid Tumor Segment by Indication

2.4.1 Melanoma Products

2.4.2 Gastrointestinal Tumor Products

2.4.3 Liver Cancer Products

2.4.4 Lung Cancer Products

2.4.5 Gynecologic Tumor Products

2.4.6 Other

2.4.7 Cell Therapy for Solid Tumor Market Size by Indication

2.4.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025 VS 2032)

2.4.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)

2.5 Cell Therapy for Solid Tumor Segment by Application

2.5.1 Melanoma

2.5.2 Lung Cancer

2.5.3 Liver Cancer

2.5.4 Gastric And Colorectal Cancer

2.5.5 Ovarian Cancer

2.5.6 Other

2.5.7 Cell Therapy for Solid Tumor Market Size by Application

2.5.7.1 Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.7.2 Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)

3 CELL THERAPY FOR SOLID TUMOR MARKET SIZE BY PLAYER

3.1 Cell Therapy for Solid Tumor Market Size Market Share by Player

3.1.1 Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026)

3.1.2 Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)

3.2 Global Cell Therapy for Solid Tumor Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion

4 CELL THERAPY FOR SOLID TUMOR BY REGION

- 4.1 Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
- 4.2 Global Cell Therapy for Solid Tumor Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
- 4.4 APAC Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
- 4.5 Europe Cell Therapy for Solid Tumor Market Size Growth (2021-2026)
- 4.6 Middle East & Africa Cell Therapy for Solid Tumor Market Size Growth (2021-2026)

5 AMERICAS

- 5.1 Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
- 5.2 Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
- 5.3 Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026)
- 6.2 APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
- 6.3 APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026)
- 7.2 Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
- 7.3 Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Cell Therapy for Solid Tumor by Region (2021-2026)
- 8.2 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026)
- 8.3 Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL CELL THERAPY FOR SOLID TUMOR MARKET FORECAST

- 10.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
 - 10.1.1 Global Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
 - 10.1.2 Americas Cell Therapy for Solid Tumor Forecast
 - 10.1.3 APAC Cell Therapy for Solid Tumor Forecast
 - 10.1.4 Europe Cell Therapy for Solid Tumor Forecast
 - 10.1.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast
- 10.2 Americas Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
 - 10.2.1 United States Market Cell Therapy for Solid Tumor Forecast
 - 10.2.2 Canada Market Cell Therapy for Solid Tumor Forecast
 - 10.2.3 Mexico Market Cell Therapy for Solid Tumor Forecast

- 10.2.4 Brazil Market Cell Therapy for Solid Tumor Forecast
- 10.3 APAC Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
 - 10.3.1 China Cell Therapy for Solid Tumor Market Forecast
 - 10.3.2 Japan Market Cell Therapy for Solid Tumor Forecast
 - 10.3.3 Korea Market Cell Therapy for Solid Tumor Forecast
 - 10.3.4 Southeast Asia Market Cell Therapy for Solid Tumor Forecast
 - 10.3.5 India Market Cell Therapy for Solid Tumor Forecast
 - 10.3.6 Australia Market Cell Therapy for Solid Tumor Forecast
- 10.4 Europe Cell Therapy for Solid Tumor Forecast by Country (2027-2032)
 - 10.4.1 Germany Market Cell Therapy for Solid Tumor Forecast
 - 10.4.2 France Market Cell Therapy for Solid Tumor Forecast
 - 10.4.3 UK Market Cell Therapy for Solid Tumor Forecast
 - 10.4.4 Italy Market Cell Therapy for Solid Tumor Forecast
 - 10.4.5 Russia Market Cell Therapy for Solid Tumor Forecast
- 10.5 Middle East & Africa Cell Therapy for Solid Tumor Forecast by Region (2027-2032)
 - 10.5.1 Egypt Market Cell Therapy for Solid Tumor Forecast
 - 10.5.2 South Africa Market Cell Therapy for Solid Tumor Forecast
 - 10.5.3 Israel Market Cell Therapy for Solid Tumor Forecast
 - 10.5.4 Turkey Market Cell Therapy for Solid Tumor Forecast
- 10.6 Global Cell Therapy for Solid Tumor Forecast by Type (2027-2032)
- 10.7 Global Cell Therapy for Solid Tumor Forecast by Application (2027-2032)
 - 10.7.1 GCC Countries Market Cell Therapy for Solid Tumor Forecast

11 KEY PLAYERS ANALYSIS

- 11.1 Iovance Biotherapeutics
 - 11.1.1 Iovance Biotherapeutics Company Information
 - 11.1.2 Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered
 - 11.1.3 Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
 - 11.1.4 Iovance Biotherapeutics Main Business Overview
 - 11.1.5 Iovance Biotherapeutics Latest Developments
- 11.2 Adaptimmune
 - 11.2.1 Adaptimmune Company Information
 - 11.2.2 Adaptimmune Cell Therapy for Solid Tumor Product Offered
 - 11.2.3 Adaptimmune Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)
 - 11.2.4 Adaptimmune Main Business Overview
 - 11.2.5 Adaptimmune Latest Developments

11.3 Immatics

11.3.1 Immatics Company Information

11.3.2 Immatics Cell Therapy for Solid Tumor Product Offered

11.3.3 Immatics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)

11.3.4 Immatics Main Business Overview

11.3.5 Immatics Latest Developments

11.4 CARSGen Therapeutics

11.4.1 CARSGen Therapeutics Company Information

11.4.2 CARSGen Therapeutics Cell Therapy for Solid Tumor Product Offered

11.4.3 CARSGen Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 CARSGen Therapeutics Main Business Overview

11.4.5 CARSGen Therapeutics Latest Developments

11.5 JW Therapeutics

11.5.1 JW Therapeutics Company Information

11.5.2 JW Therapeutics Cell Therapy for Solid Tumor Product Offered

11.5.3 JW Therapeutics Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)

11.5.4 JW Therapeutics Main Business Overview

11.5.5 JW Therapeutics Latest Developments

11.6 Legend Biotech

11.6.1 Legend Biotech Company Information

11.6.2 Legend Biotech Cell Therapy for Solid Tumor Product Offered

11.6.3 Legend Biotech Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)

11.6.4 Legend Biotech Main Business Overview

11.6.5 Legend Biotech Latest Developments

11.7 Gracell Biotechnologies

11.7.1 Gracell Biotechnologies Company Information

11.7.2 Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered

11.7.3 Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue, Gross Margin and Market Share (2021-2026)

11.7.4 Gracell Biotechnologies Main Business Overview

11.7.5 Gracell Biotechnologies Latest Developments

11.8 Fosun Kite

11.8.1 Fosun Kite Company Information

11.8.2 Fosun Kite Cell Therapy for Solid Tumor Product Offered

11.8.3 Fosun Kite Cell Therapy for Solid Tumor Revenue, Gross Margin and Market

Share (2021-2026)

11.8.4 Fosun Kite Main Business Overview

11.8.5 Fosun Kite Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Cell Therapy for Solid Tumor Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Cell Therapy for Solid Tumor Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of CAR-T Therapy

Table 4. Major Players of TCR-T Therapy

Table 5. Major Players of TIL Therapy

Table 6. Major Players of CAR-NK Therapy

Table 7. Major Players of Tumor-Infiltrating NK Or T Cells

Table 8. Major Players of Other

Table 9. Cell Therapy for Solid Tumor Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 10. Global Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & (\$ millions)

Table 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

Table 12. Major Players of Autologous Therapy

Table 13. Major Players of Allogeneic Therapy

Table 14. Major Players of Gene-Edited Therapy

Table 15. Major Players of Armored Cell Therapy

Table 16. Major Players of Combination Therapy

Table 17. Major Players of Other

Table 18. Cell Therapy for Solid Tumor Market Size CAGR by Cell Source (2021 VS 2025 VS 2032) & (\$ millions)

Table 19. Global Cell Therapy for Solid Tumor Market Size by Cell Source (2021-2026) & (\$ millions)

Table 20. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source (2021-2026)

Table 21. Major Players of Melanoma Products

Table 22. Major Players of Gastrointestinal Tumor Products

Table 23. Major Players of Liver Cancer Products

Table 24. Major Players of Lung Cancer Products

Table 25. Major Players of Gynecologic Tumor Products

Table 26. Major Players of Other

Table 27. Cell Therapy for Solid Tumor Market Size CAGR by Indication (2021 VS 2025

VS 2032) & (\$ millions)

Table 28. Global Cell Therapy for Solid Tumor Market Size by Indication (2021-2026) & (\$ millions)

Table 29. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication (2021-2026)

Table 30. Cell Therapy for Solid Tumor Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 31. Global Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (\$ millions)

Table 32. Global Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)

Table 33. Global Cell Therapy for Solid Tumor Revenue by Player (2021-2026) & (\$ millions)

Table 34. Global Cell Therapy for Solid Tumor Revenue Market Share by Player (2021-2026)

Table 35. Cell Therapy for Solid Tumor Key Players Head office and Products Offered

Table 36. Cell Therapy for Solid Tumor Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 37. New Products and Potential Entrants

Table 38. Mergers & Acquisitions, Expansion

Table 39. Global Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & (\$ millions)

Table 40. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)

Table 41. Global Cell Therapy for Solid Tumor Revenue by Country/Region (2021-2026) & (\$ millions)

Table 42. Global Cell Therapy for Solid Tumor Revenue Market Share by Country/Region (2021-2026)

Table 43. Americas Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & (\$ millions)

Table 44. Americas Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)

Table 45. Americas Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & (\$ millions)

Table 46. Americas Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

Table 47. Americas Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (\$ millions)

Table 48. Americas Cell Therapy for Solid Tumor Market Size Market Share by

Application (2021-2026)

Table 49. APAC Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & (\$ millions)

Table 50. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)

Table 51. APAC Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & (\$ millions)

Table 52. APAC Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (\$ millions)

Table 53. Europe Cell Therapy for Solid Tumor Market Size by Country (2021-2026) & (\$ millions)

Table 54. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country (2021-2026)

Table 55. Europe Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & (\$ millions)

Table 56. Europe Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (\$ millions)

Table 57. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Region (2021-2026) & (\$ millions)

Table 58. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Type (2021-2026) & (\$ millions)

Table 59. Middle East & Africa Cell Therapy for Solid Tumor Market Size by Application (2021-2026) & (\$ millions)

Table 60. Key Market Drivers & Growth Opportunities of Cell Therapy for Solid Tumor

Table 61. Key Market Challenges & Risks of Cell Therapy for Solid Tumor

Table 62. Key Industry Trends of Cell Therapy for Solid Tumor

Table 63. Global Cell Therapy for Solid Tumor Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 64. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Region (2027-2032)

Table 65. Global Cell Therapy for Solid Tumor Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 66. Global Cell Therapy for Solid Tumor Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 67. Iovance Biotherapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 68. Iovance Biotherapeutics Cell Therapy for Solid Tumor Product Offered

Table 69. Iovance Biotherapeutics Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 70. Iovance Biotherapeutics Main Business

Table 71. Iovance Biotherapeutics Latest Developments

Table 72. Adaptimmune Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 73. Adaptimmune Cell Therapy for Solid Tumor Product Offered

Table 74. Adaptimmune Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 75. Adaptimmune Main Business

Table 76. Adaptimmune Latest Developments

Table 77. Immatics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 78. Immatics Cell Therapy for Solid Tumor Product Offered

Table 79. Immatics Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 80. Immatics Main Business

Table 81. Immatics Latest Developments

Table 82. CARSGen Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 83. CARSGen Therapeutics Cell Therapy for Solid Tumor Product Offered

Table 84. CARSGen Therapeutics Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 85. CARSGen Therapeutics Main Business

Table 86. CARSGen Therapeutics Latest Developments

Table 87. JW Therapeutics Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 88. JW Therapeutics Cell Therapy for Solid Tumor Product Offered

Table 89. JW Therapeutics Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 90. JW Therapeutics Main Business

Table 91. JW Therapeutics Latest Developments

Table 92. Legend Biotech Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 93. Legend Biotech Cell Therapy for Solid Tumor Product Offered

Table 94. Legend Biotech Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 95. Legend Biotech Main Business

Table 96. Legend Biotech Latest Developments

Table 97. Gracell Biotechnologies Details, Company Type, Cell Therapy for Solid Tumor Area Served and Its Competitors

Table 98. Gracell Biotechnologies Cell Therapy for Solid Tumor Product Offered

Table 99. Gracell Biotechnologies Cell Therapy for Solid Tumor Revenue (\$ million),
Gross Margin and Market Share (2021-2026)

Table 100. Gracell Biotechnologies Main Business

Table 101. Gracell Biotechnologies Latest Developments

Table 102. Fosun Kite Details, Company Type, Cell Therapy for Solid Tumor Area
Served and Its Competitors

Table 103. Fosun Kite Cell Therapy for Solid Tumor Product Offered

Table 104. Fosun Kite Cell Therapy for Solid Tumor Revenue (\$ million), Gross Margin
and Market Share (2021-2026)

Table 105. Fosun Kite Main Business

Table 106. Fosun Kite Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Cell Therapy for Solid Tumor Report Years Considered
- Figure 2. Research Objectives
- Figure 3. Research Methodology
- Figure 4. Research Process and Data Source
- Figure 5. Global Cell Therapy for Solid Tumor Market Size Growth Rate (2021-2032) (\$ millions)
- Figure 6. Cell Therapy for Solid Tumor Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 7. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2025)
- Figure 8. Cell Therapy for Solid Tumor Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 9. Global Cell Therapy for Solid Tumor Market Size Market Share by Type in 2025
- Figure 10. Global Cell Therapy for Solid Tumor Market Size Market Share by Cell Source in 2025
- Figure 11. Global Cell Therapy for Solid Tumor Market Size Market Share by Indication in 2025
- Figure 12. Cell Therapy for Solid Tumor in Melanoma
- Figure 13. Global Cell Therapy for Solid Tumor Market: Melanoma (2021-2026) & (\$ millions)
- Figure 14. Cell Therapy for Solid Tumor in Lung Cancer
- Figure 15. Global Cell Therapy for Solid Tumor Market: Lung Cancer (2021-2026) & (\$ millions)
- Figure 16. Cell Therapy for Solid Tumor in Liver Cancer
- Figure 17. Global Cell Therapy for Solid Tumor Market: Liver Cancer (2021-2026) & (\$ millions)
- Figure 18. Cell Therapy for Solid Tumor in Gastric And Colorectal Cancer
- Figure 19. Global Cell Therapy for Solid Tumor Market: Gastric And Colorectal Cancer (2021-2026) & (\$ millions)
- Figure 20. Cell Therapy for Solid Tumor in Ovarian Cancer
- Figure 21. Global Cell Therapy for Solid Tumor Market: Ovarian Cancer (2021-2026) & (\$ millions)
- Figure 22. Cell Therapy for Solid Tumor in Other
- Figure 23. Global Cell Therapy for Solid Tumor Market: Other (2021-2026) & (\$ millions)
- Figure 24. Global Cell Therapy for Solid Tumor Market Size Market Share by

Application in 2025

Figure 25. Global Cell Therapy for Solid Tumor Revenue Market Share by Player in 2025

Figure 26. Global Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)

Figure 27. Americas Cell Therapy for Solid Tumor Market Size 2021-2026 (\$ millions)

Figure 28. APAC Cell Therapy for Solid Tumor Market Size 2021-2026 (\$ millions)

Figure 29. Europe Cell Therapy for Solid Tumor Market Size 2021-2026 (\$ millions)

Figure 30. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2021-2026 (\$ millions)

Figure 31. Americas Cell Therapy for Solid Tumor Value Market Share by Country in 2025

Figure 32. United States Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 33. Canada Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 34. Mexico Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 35. Brazil Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 36. APAC Cell Therapy for Solid Tumor Market Size Market Share by Region in 2025

Figure 37. APAC Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

Figure 38. APAC Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)

Figure 39. China Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 40. Japan Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 41. South Korea Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 42. Southeast Asia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 43. India Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 44. Australia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 45. Europe Cell Therapy for Solid Tumor Market Size Market Share by Country

in 2025

Figure 46. Europe Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

Figure 47. Europe Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)

Figure 48. Germany Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 49. France Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 50. UK Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 51. Italy Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 52. Russia Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 53. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Region (2021-2026)

Figure 54. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Type (2021-2026)

Figure 55. Middle East & Africa Cell Therapy for Solid Tumor Market Size Market Share by Application (2021-2026)

Figure 56. Egypt Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 57. South Africa Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 58. Israel Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 59. Turkey Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 60. GCC Countries Cell Therapy for Solid Tumor Market Size Growth 2021-2026 (\$ millions)

Figure 61. Americas Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 62. APAC Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 63. Europe Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 64. Middle East & Africa Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 65. United States Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 66. Canada Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 67. Mexico Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 68. Brazil Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 69. China Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 70. Japan Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 71. Korea Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 72. Southeast Asia Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 73. India Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 74. Australia Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 75. Germany Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 76. France Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 77. UK Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 78. Italy Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 79. Russia Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 80. Egypt Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 81. South Africa Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 82. Israel Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 83. Turkey Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

Figure 84. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Type (2027-2032)

Figure 85. Global Cell Therapy for Solid Tumor Market Size Market Share Forecast by Application (2027-2032)

Figure 86. GCC Countries Cell Therapy for Solid Tumor Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Cell Therapy for Solid Tumor Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/GBD7CCAE4C79EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBD7CCAE4C79EN.html>